Prespecified secondary analysis of VESALIUS-CV (7557 patients without prior MI or stroke): higher Lp(a) was associated with major coronary events (HR 1.15 per 100 nmol/L). Evolocumab's relative benefit vs placebo was similar regardless of Lp(a) (HR 0.59 vs 0.65).
Secondary analysisn = 7,557
Monguillon et al. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial